FR2554718B1
(fr)
*
|
1983-11-14 |
1986-04-04 |
Ethypharm Sa |
Nouvelles formes galeniques du sulpiride utilisables par voie orale
|
FR2556964A1
(fr)
*
|
1983-12-23 |
1985-06-28 |
Ile De France |
Nouvelles formes galeniques du sulpiride utilisables par voie orale
|
JPS60221078A
(ja)
*
|
1984-04-18 |
1985-11-05 |
Morinaga Milk Ind Co Ltd |
有用微生物粉末の粒状製品およびその製造法
|
IT1180507B
(it)
*
|
1984-06-29 |
1987-09-23 |
Roberto Valducci |
Procedimento per la preparazione di etofibrato o sostanze di pari o simili caratteristiche, in microgunuli-ritardo e prodotto ottenuto con tale procedimento
|
FR2602423B1
(fr)
*
|
1986-08-08 |
1989-05-05 |
Ethypharm Sa |
Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
|
FR2627696B1
(fr)
*
|
1988-02-26 |
1991-09-13 |
Fournier Innovation Synergie |
Nouvelle forme galenique du fenofibrate
|
FR2737121B1
(fr)
*
|
1995-07-27 |
1997-10-03 |
Cl Pharma |
Nouvelles formulations galeniques du fenofibrate et leurs applications
|
DE19608750A1
(de)
*
|
1996-03-06 |
1997-09-11 |
Durachemie Gmbh & Co Kg |
Verfahren zur Herstellung von Fenofibrat-Präparaten
|
FR2758461A1
(fr)
*
|
1997-01-17 |
1998-07-24 |
Pharma Pass |
Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
|
FR2758459B1
(fr)
*
|
1997-01-17 |
1999-05-07 |
Pharma Pass |
Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
|
DE19858789A1
(de)
|
1998-12-18 |
2000-06-21 |
Bayer Ag |
Kombination von Cerivastatin und Fibraten
|
US6814977B1
(en)
|
1998-12-18 |
2004-11-09 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6838091B2
(en)
|
1998-12-18 |
2005-01-04 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US7014864B1
(en)
|
1998-12-18 |
2006-03-21 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6180138B1
(en)
|
1999-01-29 |
2001-01-30 |
Abbott Laboratories |
Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
|
US6368622B2
(en)
|
1999-01-29 |
2002-04-09 |
Abbott Laboratories |
Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
|
US6383517B1
(en)
|
1999-01-29 |
2002-05-07 |
Abbott Laboratories |
Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
|
US6719999B2
(en)
|
1999-03-31 |
2004-04-13 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6465011B2
(en)
|
1999-05-29 |
2002-10-15 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6372251B2
(en)
|
1999-06-11 |
2002-04-16 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6982281B1
(en)
|
2000-11-17 |
2006-01-03 |
Lipocine Inc |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US7863331B2
(en)
|
1999-07-09 |
2011-01-04 |
Ethypharm |
Pharmaceutical composition containing fenofibrate and method for the preparation thereof
|
FR2795961B1
(fr)
|
1999-07-09 |
2004-05-28 |
Ethypharm Lab Prod Ethiques |
Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
|
US6531158B1
(en)
|
2000-08-09 |
2003-03-11 |
Impax Laboratories, Inc. |
Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
|
US6982251B2
(en)
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
FR2819720B1
(fr)
|
2001-01-22 |
2004-03-12 |
Fournier Lab Sa |
Nouveaux comprimes de fenofibrate
|
US7071181B2
(en)
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
EP1355644B1
(en)
|
2001-01-26 |
2006-06-28 |
Schering Corporation |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
MEP27808A
(en)
|
2001-01-26 |
2010-10-10 |
Schering Corp |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
ATE345793T1
(de)
|
2001-09-21 |
2006-12-15 |
Schering Corp |
Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
EP1553928A1
(en)
*
|
2002-09-24 |
2005-07-20 |
Ranbaxy Laboratories, Ltd. |
Oral pharmaceutical compositions of fenofibrate having high bioavailability
|
CA2504916A1
(en)
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
AU2003284625A1
(en)
*
|
2002-11-22 |
2004-06-18 |
Kunimine Industries Co., Ltd. |
Granular composition and process for producing the same
|
MXPA05005736A
(es)
*
|
2002-12-17 |
2005-08-16 |
Abbott Gmbh & Co Kg |
Formulacion que comprende acido fenofibrico, una sal fisiologicamente aceptable o derivado del mismo.
|
EP1832285A1
(en)
*
|
2002-12-17 |
2007-09-12 |
Abbott GmbH & Co. KG |
Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
|
WO2004081004A1
(en)
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
WO2004081003A1
(en)
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
ES2311806T3
(es)
|
2003-03-07 |
2009-02-16 |
Schering Corporation |
Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
MXPA06000111A
(es)
*
|
2003-07-02 |
2006-04-27 |
Abbott Lab |
Proceso para preparar formulaciones de farmacos que regulan lipidos.
|
US8062664B2
(en)
|
2003-11-12 |
2011-11-22 |
Abbott Laboratories |
Process for preparing formulations of lipid-regulating drugs
|
EP1785133A1
(en)
|
2005-11-10 |
2007-05-16 |
Laboratoires Fournier S.A. |
Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
|
WO2008075320A2
(en)
*
|
2006-12-21 |
2008-06-26 |
Ranbaxy Laboratories Limited |
Antilipidemic pharmaceutical compositions and process for preparation thereof
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
WO2016033549A2
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
WO2016033556A1
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
|
WO2016205423A2
(en)
|
2015-06-15 |
2016-12-22 |
Lipocine Inc. |
Composition and method for oral delivery of androgen prodrugs
|
WO2018098501A1
(en)
|
2016-11-28 |
2018-05-31 |
Lipocine Inc. |
Oral testosterone undecanoate therapy
|
WO2020018974A1
(en)
|
2018-07-20 |
2020-01-23 |
Lipocine Inc. |
Liver disease
|